- 0
- 0
- 约2.79千字
- 约 21页
- 2023-12-10 发布于北京
- 举报
Riskofsubsequentcancerdiagnosisinpatientstreatedwith3Dconformal,intensitymodulated,orprotonbeamradiationtherapy
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Radiationandsecondcancerrisk
PresentedByMichaelXiangat2019ASCOAnnualMeeting
ComparisonsamongmodernRTmodalities
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Aim,methodology,anddatasource
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Methods:Cohortidentification(patientselection)
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Methods:Cohortidentification(tumortypeselection)
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Methods:Determinationofsecondcancer
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Methods:Determinationofsecondcancer
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Methods:Statisticalyses
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Methods:18variablesusedforadjustment
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Results:Cohortdescription
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Results:TumortypedistributionbyRTmodality
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Results:Absolutecrudeidenceofsecondcancer
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Results:IMRThassimilarsecondcancersas3DCRT
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Results:PBRTsignificantlylesssecondcancervsIMRT
PresentedByMichaelXiangat2019ASCOAnnualMeeting
Results:BenefitfavoringPBRTseenacrossal
原创力文档

文档评论(0)